
We claim:

1. A compound of the following formula (I), or a pharmaceutical acceptable salt thereof:




(I)

In the formula (I),

W represents hydrogen, deuterium,C_{1-6} alkyl, in which C_{1-6} alkyl is substituted by one or more selected from the group consisting of deuterium, halogen, CN or OR_9;

R_1 represents C_{1-6} alkyl, or C_{3-6} cycloalkyl,; anyone of which can be optionally substituted by one or more selected from the group consisting of deuterium, or halogen;

R_2 represents the ring structures selected from the group consisting of A8, or A9 groups:



(A8) (A9) ,

in which the"〰" represents the bond of attachment to the remainder of the molecular;

R_3-R_5 each independently represents hydrogen, or deuteriuml;

R_6 and R_7 each independently represents hydrogen, or deuterium;

R_9 represents C_{1-6} alkyl.

2. The compound of the formula (I), or a pharmaceutical acceptable salt thereof of claim 1, wherein W represents $-(CH_2)_{1-3}OCH_3$, $-(CH_2)_{1-3}CN$, $-(CH_2)_{1-3}CHF_2$, $-(CH_2)_{1-3}CF_2CH_3$, $-(CH_2)_{1-3}CF_3$ or $-(CH_2)_{1-3}OCF_3$.


3. The compound of the formula (I), or a pharmaceutical acceptable salt thereof of claim 1, wherein W represents $-(CH_2)_{1-3}OCH_3$, $-(CH_2)_{1-3}CN$, $-(CH_2)_{1-3}CHF_2$ or $-(CH_2)_{1-3}OCF_3$.

4. The compound of the formula (I), or a pharmaceutical acceptable salt thereof of


claim 1, wherein W represents -$(CH_2)_{1-3}OCH_3$, -$(CH_2)_{1-3}CN$ or -$(CH_2)_{1-3}CHF_2$.

5. The compound of the formula (I), or a pharmaceutical acceptable salt thereof of claim 1, wherein W represents -$(CH_2)_{1-3}OCH_3$ or -$(CH_2)_{1-3}CN$.


6. The compound of the formula (I), or a pharmaceutical acceptable salt thereof of any one of claims 1-5, wherein the compound of formula (I) is a compound of formula (IIa), (IIb), (IIc) or (IId):




(IIa)



(IIb)




(IIc)




(IId)

in which R_1 to R_7 are as defined in claim 1.

7. The compound of the formula (I), or a pharmaceutical acceptable salt thereof of any one of claims 1-5, wherein the compound of formula (I) is represented by any one of the following formulae (Xh) to (Xi):.



(Xh)




(Xi)


in which W, R_1, R_3, R_4, R_5, R_6 and R_7 are as defined in claim 1.

8. The compound of the formula (I), or a pharmaceutical acceptable salt thereof of any

one of claims 1-5, wherein the compound of formula (I) is a compound of formula (IIIa), or (IIIb):




(IIIa)




(IIIb)

in which W, R_2, R_3, R_4, R_5, R_6 and R_7 are as defined in claim 1; m = 0, 1 or 2.


9. The compound of the formula (I), or a pharmaceutical acceptable salt thereof of any one of claims 1-5, wherein the compound of the formula (I) is selected from the following:




E19




E19-01




E19-02




E20




E20-01




E20-02




E22




E22-01




E22-02




E23-01




E23-02




E23




E33-01




E33-02



E33-03



E33-04



10. Use of the compound of the formula (I), or a pharmaceutical acceptable salt thereof according to any one of claims 1-9 in the preparation of a medicine for treating and/or preventing a disease modulated by IL-17A.

11. Use of the compound of the formula (I), or a pharmaceutical acceptable salt thereof according to any one of claims 1-9 for treating and/or preventing a disease mediated by IL-17A.

12. A method of treating and/preventing a disease mediated by IL-17A, comprising the step of administrating a therapeutically effective amount of the compound of the formula (I), or a pharmaceutical acceptable salt thereof according to any one of claims 1-9 into a subject to be treated.

13. A pharmaceutical composition comprising the compound of the formula (I), or a pharmaceutical acceptable salt thereof according to any one of claims 1-9.